ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $89.60 Average PT from Analysts


Share on StockTwits

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been assigned a consensus recommendation of “Buy” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $90.67.

Several brokerages recently issued reports on ALXO. HC Wainwright began coverage on shares of ALX Oncology in a report on Wednesday, February 10th. They set a “buy” rating and a $100.00 price target on the stock. Credit Suisse Group boosted their target price on shares of ALX Oncology from $62.00 to $98.00 and gave the stock an “outperform” rating in a research note on Thursday, February 11th. Cantor Fitzgerald increased their price target on ALX Oncology from $64.00 to $103.00 and gave the company an “overweight” rating in a research note on Wednesday, January 6th. UBS Group initiated coverage on ALX Oncology in a research report on Tuesday, April 6th. They set a “buy” rating and a $96.00 price objective on the stock. Finally, Piper Sandler upped their target price on ALX Oncology from $78.00 to $97.00 and gave the stock an “overweight” rating in a report on Tuesday, December 15th.

NASDAQ ALXO traded down $8.41 on Tuesday, hitting $63.77. 199,984 shares of the company’s stock were exchanged, compared to its average volume of 244,005. ALX Oncology has a 52 week low of $28.01 and a 52 week high of $117.45. The stock has a 50-day moving average of $74.52 and a 200-day moving average of $68.20.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Thursday, March 18th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.13). As a group, sell-side analysts expect that ALX Oncology will post -2.29 earnings per share for the current year.

In other news, insider Sophia Randolph sold 7,387 shares of the company’s stock in a transaction on Wednesday, March 10th. The shares were sold at an average price of $74.34, for a total value of $549,149.58. Following the sale, the insider now directly owns 207,227 shares of the company’s stock, valued at approximately $15,405,255.18. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Jaume Pons sold 16,700 shares of the stock in a transaction on Monday, March 22nd. The stock was sold at an average price of $68.49, for a total transaction of $1,143,783.00. Following the sale, the chief executive officer now owns 568,046 shares of the company’s stock, valued at $38,905,470.54. The disclosure for this sale can be found here.

Institutional investors have recently modified their holdings of the business. Pacer Advisors Inc. bought a new position in shares of ALX Oncology in the 4th quarter worth about $38,000. Lindbrook Capital LLC increased its holdings in ALX Oncology by 366.7% in the fourth quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock worth $60,000 after purchasing an additional 550 shares in the last quarter. Penserra Capital Management LLC acquired a new position in ALX Oncology in the fourth quarter valued at approximately $73,000. First Mercantile Trust Co. lifted its stake in ALX Oncology by 101.5% in the fourth quarter. First Mercantile Trust Co. now owns 1,209 shares of the company’s stock valued at $104,000 after buying an additional 609 shares during the period. Finally, Morgan Stanley acquired a new stake in shares of ALX Oncology during the 3rd quarter worth approximately $72,000. Hedge funds and other institutional investors own 73.45% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma.

Further Reading: Equal Weight Rating

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.